Clinical Trials

Kadmon is developing innovative therapies for patients

To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or email clinical@kadmon.com.

KD025 in Chronic Graft-Versus-Host Disease

Brief

KD025 in patients with cGVHD after at least 2 prior lines of systemic therapy

Information
Phase: 2
Study Ref. #: KD025-213 (ROCKstar)

KD025 in Chronic Graft-Versus-Host Disease

Brief

Trial of KD025 in patients with steroid-dependent or steroid-refractory cGVHD and active disease

Information
Phase: 2
Study Ref. #: KD025-208

KD025 in Idiopathic Pulmonary Fibrosis

Brief

KD025 in patients with IPF who have received or been offered pirfenidone and/or nintedanib

Information
Phase: 2
Study Ref. #: KD025-207

Tesevatinib in Autosomal Dominant Polycystic Kidney Disease

Brief

Tesevatinib in patients with autosomal dominant polycystic kidney disease

Information
Phase: 2
Study Ref. #: KD019-211

Tesevatinib in Autosomal Recessive Polycystic Kidney Disease

Brief

Tesevatinib liquid formulation in pediatric patients with ARPKD

Information
Phase: 1
Study Ref. #: KD019-103